Tony W. Ho

2018

In 2018, Tony W. Ho earned a total compensation of $4.1M as EVP, Research and Development at CRISPR Therapeutics AG, a 7% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$258,321
Option Awards$3,466,189
Salary$414,980
Other$9,625
Total$4,149,115

Ho received $3.5M in option awards, accounting for 84% of the total pay in 2018.

Ho also received $258.3K in non-equity incentive plan, $415K in salary and $9.6K in other compensation.

Rankings

In 2018, Tony W. Ho's compensation ranked 2,660th out of 14,244 executives tracked by ExecPay. In other words, Ho earned more than 81.3% of executives.

ClassificationRankingPercentile
All
2,660
out of 14,244
81st
Division
Manufacturing
985
out of 5,759
83rd
Major group
Chemicals And Allied Products
337
out of 2,122
84th
Industry group
Drugs
275
out of 1,811
85th
Industry
Biological Products, Except Diagnostic Substances
57
out of 339
83rd
Source: SEC filing on April 30, 2019.

Ho's colleagues

We found four more compensation records of executives who worked with Tony W. Ho at CRISPR Therapeutics AG in 2018.

2018

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2018

James Kasinger

CRISPR Therapeutics AG

General Counsel

2018

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

2018

Rodger Novak

CRISPR Therapeutics AG

President

News

In-depth

You may also like